Norifaz (Risedronate Sodium)

Risedronate Sodium, the active ingredient in Norifaz, is a bisphosphonate presented as a tablet for oral use. It treats osteoporosis and Paget's disease of bone in adult patients, helping to reduce bone loss and fracture risk.

GNH USA supplies Norifaz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Norifaz belongs to the bisphosphonate class and is used to manage disorders of bone remodeling.

Osteoporosis: reduces the risk of vertebral, hip and other fractures by inhibiting bone resorption. Paget's disease of bone: normalises abnormal bone turnover and alleviates associated pain and deformities.

Common Side Effects: - Abdominal pain or discomfort - Nausea or dyspepsia - Constipation or diarrhoea - Musculoskeletal pain - Headache - Flatulence

Serious or Rare Side Effects: - Osteonecrosis of the jaw - Atypical femur fracture - Severe allergic reaction (anaphylaxis, rash, swelling) - Esophageal ulceration or irritation - Acute renal failure in susceptible individuals

Before initiating therapy, clinicians should evaluate renal function, ensure adequate calcium and vitamin D intake, and review any history of gastrointestinal disorders.

Renal function assessment: confirm creatinine clearance is adequate. Calcium/vitamin D supplementation: maintain normal serum levels. Avoid lying down for at least 30 minutes after ingestion: reduces oesophageal irritation. Contraindicated in patients with active oesophageal disease: avoid risk of ulceration. Monitor for hypocalcaemia: check serum calcium periodically. Store at ambient temperature: keep in original container, protect from moisture and heat.

Risedronate may have clinically relevant interactions that require attention.

Major Interactions (Avoid): - Calcium, magnesium, aluminium or iron supplements taken concurrently: markedly reduces risedronate absorption. - Antacids containing aluminium or magnesium: interfere with drug bioavailability. - Other bisphosphonates or bone‑active agents: increase risk of oversuppression of bone turnover.

Moderate Interactions (Monitor Closely): - Systemic corticosteroids: may exacerbate bone loss. - Warfarin: potential for altered INR, monitor coagulation parameters. - Loop or thiazide diuretics: affect calcium balance, watch for hypocalcaemia.